Kleiner Perkins

China biotech investor, executive James Li on the rise of China biotech and why it’s only just the beginning

Plus: VCs back a Lexeo spinout, and more

Developers of programmable CAR T therapies and human-compatible organs for transplantation garner nine-figure fundings

Plus: Prevail, Scribe in gene editing deal and updates from Ensoma, NewLimit and Drug Farm

What we promised 30 years ago still holds true, even as our scope and global reach have grown: BioCentury’s 30th anniversary collection

Cell therapy business adds armored CAR T platform, handful of therapies, but won’t advance prostate cancer program 

Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest

Plus Arsenal raises $220M and updates from Roche, Phoremost, Synlogic and more

Budget-priced $247M acquisition of epigenetics pioneer with slow-selling drug could deliver more value to Epizyme’s shareholders via CVR

Company building to remain the focus of VC as it adds Celgene, Kleiner Perkins alum